ITCH
protein-codingitchy E3 ubiquitin protein ligase, the group of HECT domain containing|C2 domain containing|MicroRNA protein coding host genes
Gene summary
This gene encodes a member of the Nedd4 family of HECT domain E3 ubiquitin ligases. HECT domain E3 ubiquitin ligases transfer ubiquitin from E2 ubiquitin-conjugating enzymes to protein substrates, thus targeting specific proteins for lysosomal degradation. The encoded protein plays a role in multiple cellular processes including erythroid and lymphoid cell differentiation and the regulation of immune responses. Mutations in this gene are a cause of syndromic multisystem autoimmune disease. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Mar 2012]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~148.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0013245
Submitter: ClinGen
The first report indicating a relationship of the ITCH gene with autosomal recessive syndromic multisystem autoimmune disease due to ITCH deficiency was reported by Lohr et al., 2010 (PMID 20170897). This publication featured 10 children from an extended family of Old Order Amish, each presenting with a syndrome characterized by organomegaly, failure to thrive, developmental delay, dysmorphic features, and autoimmune inflammatory cell infiltration of the lungs, liver, and gut. It is estimated that fewer than 1,000 people in the US have this disease (www.rarediseases.info.nih.gov). Numerous variants have been reported in the ITCH gene, in both ClinVar and in LOVD (https://databases.lovd.nl/shared/genes/ITCH). Evidence supporting this gene-disease relationship includes case-level data, segregation data, functional data, and model organisms. This gene-disease relationship was established in humans 15 years ago, and has ITCH been studied in cell and animal models for over 30 years; therefore, a significant amount of case-level data, segregation data, and experimental data is available. The maximum score for genetic evidence (12 points) has been reached, and 4 points for experimental evidence have been obtained. This curation effort is exhaustive in terms of all known clinical reports of ITCH-related disease, and includes all known experimental evidence regarding ITCH variants known to cause disease in humans. The mechanism for the gene-disease relationship is protein loss of function, as the ITCH protein product is a member of an E3 ubiquitin ligase that helps degrade other proteins involved in the immune response. A list of the targets of this ubiquitin ligase and their roles in the immune response is provided by Yin et al, 2020 (PMID 32165318). In summary, ITCH is DEFINITIVELY associated with autosomal recessive syndromic multisystem autoimmune disease due to ITCH deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Primary Immunodeficiencies Gene Curation Expert Panel on August 19, 2025. **Diabetes Addendum by MDEP GCEP:** Autosomal recessive variants in the ITCH gene, which encodes an E3 ubiquitin ligase, were first reported in 2010 in association with multisystem autoimmune disease, dysmorphic features, developmental abnormalities, and diabetes in humans (PMID: 20170897). In this study, ten Old Order Amish children were identified with organomegaly, failure to thrive, developmental delay, dysmorphic features, and autoimmune inflammatory infiltration of the lungs, liver, and gut. However, only one subject was diagnosed with type 1 diabetes. The clinical manifestations of multisystem autoimmunity varied: two children had enteropathy, and six developed autoantibodies and one or more organ-specific autoimmune diseases, including autoimmune hepatitis, hypothyroidism and type 1 diabetes. In 2019, a case described a 1-year-old girl with ITCH deficiency due to a homozygous splice variant c.1693-1G>A, who developed a systemic autoimmune disease including autoimmune type 1 diabetes as part of a multisystem phenotype. The diagnosis was supported by elevated islet-cell antibodies, GAD antibodies, and insulin autoantibodies, confirming an autoimmune mechanism. While Amish patients with ITCH variants had diabetes in only a minority (~10%), this report provided further evidence that biallelic ITCH variants can directly manifest with autoimmune diabetes alongside hepatitis, thyroiditis, and other immune-mediated conditions (PMID: 30705142). Subsequently, Patel et al. (2021) reported a patient with compound heterozygous ITCH variants who presented with growth failure, very-early-onset inflammatory bowel disease, arthritis, uveitis, psoriasis, and developed diabetes at age 14 that was insulin- requiring and autoantibody (GAD65) positive. Although glycemic control improved after hematopoietic cell transplantation (HCT) with temporary discontinuation of insulin, long- acting insulin had to be resumed. Unlike other autoimmune features that resolved post- HCT, the diabetes persisted, reflecting permanent β-cell destruction (PMID: 33894394). While evidence for a role of ITCH in diabetes as a component of this rare autoimmune disorder is currently limited to three cases, it is prudent for individuals presenting with features of ITCH-related disorders and found to have biallelic pathogenic ITCH variants to undergo antibody testing and glycemic screening to enable early diagnosis and treatment for diabetes. While diabetes does not appear to be an isolated presenting feature in the few cases of ITCH-related multisystem autoimmune disease to date, identification of a biallelic pathogenic or likely pathogenic ITCH variant in an individual presenting with diabetes warrants awareness and screening for other autoimmune features. This amendment was approved by the Monogenic Diabetes GCEP on meeting date September 24, 2025.
Inheritance Pattern: AR
Disease ID:MONDO:0013245
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0013245
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0013245
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0013245
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0013245
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0013245
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious; Craniofacial; Endocrine; Gastrointestinal; Neurologic; Pulmonary
Intervention: Allergy/Immunology/Infectious; Endocrine
Rationale: Individuals typically present with multisystem malformations, which may aid in clinical recognition, but awareness of disease may allow corticosteroid and other related immunosuppressive treatment related to autoimmune manifestations (including hypothyroidism, which responds to standard hormone replacement therapy), as well as awareness of the risk of frequent infections, which can allow prophylaxis/surveillance for infectious diseases, and early and aggressive treatment of infections
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ITCH variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_031483.7. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 8 | 140 | 1 | 149 | ||
| missense | 178 | 8 | 186 | |||
| nonsense | 7 | 1 | 8 | |||
| start loss | 1 | 1 | ||||
| frameshift | 6 | 2 | 1 | 9 | ||
| splice donor/acceptor (+/-2bp) | 4 | 8 | 12 | |||
| Total | 13 | 7 | 196 | 148 | 1 | 365 |
Highest pathogenic variant AF is 0.0000034228383
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_113671.3 | 23 | MANE Select | |
| Ensembl | ENSP00000363998.4 | 23 | MANE Select | |
| RefSeq | NP_001244066.1 | 24 | Standard | |
| RefSeq | NP_001244067.1 | 21 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| itchb | Danio rerio | Structure: posterior lateral line primordium Quality: disorganized abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human)
- Endocytosis - Homo sapiens (human)
- Ubiquitin mediated proteolysis - Homo sapiens (human)
- TNF signaling pathway - Homo sapiens (human)
- TGF-Ncore
Biological Process
- protein polyubiquitination
- regulation of cell growth
- positive regulation of T cell anergy
- ubiquitin-dependent protein catabolic process
- apoptotic process
Molecular Function
- ubiquitin-protein transferase activity
- protein binding
- ligase activity
- ubiquitin-like protein transferase activity
- ribonucleoprotein complex binding
Cellular Component
- nucleoplasm
- cytoplasm
- early endosome
- cytosol
- plasma membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000262650
- Coding exons
- 24
- Length
- 148158
- Individuals with no LoFs
- 125737
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 9
- Defined
- 125746
- p
- 0.0000358
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 3.58 | 263 | 485 | 0.542 | 0.0000252 | 5924 |
| Missense (PolyPhen) | 59 | 183.3 | 0.32187 | 2145 | ||
| Synonymous | -1.03 | 181 | 164 | 1.10 | 0.00000824 | 1654 |
| Loss of Function | 6.36 | 7 | 60.3 | 0.116 | 0.00000325 | 681 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0.00023 | 0.00014 | rare |
| European (Non-Finnish) | 0.000027 | 0.000026 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:14602072, PubMed:17028573, PubMed:16387660, PubMed:18718448, PubMed:18718449, PubMed:11046148, PubMed:19592251, PubMed:19116316, PubMed:19881509, PubMed:20491914, PubMed:20392206, PubMed:20068034, PubMed:23146885, PubMed:24790097, PubMed:25631046). Catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation (PubMed:17028573, PubMed:18718448, PubMed:19131965, PubMed:19881509). Involved in the control of inflammatory signaling pathways (PubMed:19131965). Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways (PubMed:19131965). Promotes the association of the complex after TNF stimulation (PubMed:19131965). Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains (PubMed:19131965). This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFKB1 (PubMed:19131965). Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways (PubMed:19592251). Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response (PubMed:18718448, PubMed:20491914). Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages (PubMed:18718448). Mediates JUN ubiquitination and degradation (By similarity). Mediates JUNB ubiquitination and degradation (PubMed:16387660). Critical regulator of type 2 helper T (Th2) cell cytokine production by inducing JUNB ubiquitination and degradation (By similarity). Involved in the negative regulation of MAVS-dependent cellular antiviral responses (PubMed:19881509). Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation (PubMed:19881509). Following ligand stimulation, regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway probably by modulating PI42KA activity (PubMed:23146885). Ubiquitinates PI4K2A and negatively regulates its catalytic activity (PubMed:23146885). Ubiquitinates chemokine receptor CXCR4 and regulates sorting of CXCR4 to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM (PubMed:14602072, PubMed:23146885). Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination (PubMed:17028573, PubMed:18628966, PubMed:23886940). Ubiquitinates SNX9 (PubMed:20491914). Ubiquitinates MAP3K7 through 'Lys-48'- linked conjugation (By similarity). Involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP (PubMed:20068034). Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID (PubMed:20392206). Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:25631046). {ECO:0000250|UniProtKB:Q8C863, ECO:0000269|PubMed:14602072, ECO:0000269|PubMed:16387660, ECO:0000269|PubMed:17028573, ECO:0000269|PubMed:18628966, ECO:0000269|PubMed:18718448, ECO:0000269|PubMed:18718449, ECO:0000269|PubMed:19116316, ECO:0000269|PubMed:19131965, ECO:0000269|PubMed:19592251, ECO:0000269|PubMed:19881509, ECO:0000269|PubMed:20068034, ECO:0000269|PubMed:20392206, ECO:0000269|PubMed:20491914, ECO:0000269|PubMed:23146885, ECO:0000269|PubMed:23886940, ECO:0000269|PubMed:24790097, ECO:0000269|PubMed:25631046}.;
- Disease
- DISEASE: Autoimmune disease, multisystem, with facial dysmorphism (ADMFD) [MIM:613385]: A disorder characterized by organomegaly, failure to thrive, developmental delay, dysmorphic features and autoimmune inflammatory cell infiltration of the lungs, liver and gut. {ECO:0000269|PubMed:20170897}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.0847
Intolerance Scores
- LoFtool
- 0.194
- RVIS EVS
- -1.09
- RVIS percentile EVS
- 7.05
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.871
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |